BioDelivery Sciences International, Inc. (BDSI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.44+0.01 (+0.41%)
As of 1:17 PM EDT. Market open.
People also watch:
SPPIBCRXFOLDVNDAARRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open2.43
Prev Close2.43
Bid2.45 x 1000
Ask2.46 x 1000
Day's Range2.41 - 2.47
52wk Range1.86 - 7.79
1y Target EstN/A
Market Cap130.88M
P/E Ratio (ttm)-2.84
Beta0.76
Volume236,705
Avg Vol (3m)941,663
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube16 days ago

    ETF’s with exposure to BioDelivery Sciences International, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to BioDelivery Sciences International, Inc. Here are 5 ETF’s with the largest exposure to BDSI-US. Comparing the performance and risk of BioDelivery Sciences International, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Capital Cube19 days ago

    BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis BioDelivery Sciences International, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of BioDelivery Sciences International, Inc. – Depomed, Inc., AcelRx Pharmaceuticals, Inc., Galena Biopharma, Inc., Insys Therapeutics, Inc., Titan Pharmaceuticals, Inc., MediciNova, Inc., Pfizer Inc. and Johnson ... Read more (Read more...)

  • BioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up
    Zacks20 days ago

    BioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up

    BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.